ID   HCC4006-GR-high
AC   CVCL_S698
DR   cancercelllines; CVCL_S698
DR   Cosmic; 1896431
DR   Wikidata; Q54881725
RX   PubMed=23542356;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: Epithelial cell; CL=CL_0000066.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1269 ! HCC4006
SX   Male
AG   >50Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 14-08-25; Version: 17
//
RX   PubMed=23542356; DOI=10.1158/0008-5472.CAN-12-4136; PMCID=PMC4506773;
RA   Shien, Kazuhiko
RA   Toyooka, Shinichi
RA   Yamamoto, Hiromasa
RA   Soh, Junichi
RA   Jida, Masaru
RA   Thu, Kelsie L.
RA   Hashida, Shinsuke
RA   Maki, Yuho
RA   Ichihara, Eiki
RA   Asano, Hiroaki
RA   Tsukuda, Kazunori
RA   Takigawa, Nagio
RA   Kiura, Katsuyuki
RA   Gazdar, Adi F.
RA   Lam, Wan L.
RA   Miyoshi, Shinichiro
RT   "Acquired resistance to EGFR inhibitors is associated with a
RT   manifestation of stem cell-like properties in cancer cells.";
RL   Cancer Res. 73:3051-3061(2013).
//